BackAptahem AB (publ) Overview

Aptahem AB (publ) Other Current Liabilities

Latest other current liabilities for APTA.ST: $750K.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$748000.00
↓ 44.18% YoYΔ $-592000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Aptahem AB (publ) Other Current Liabilities History

Loading

Aptahem AB (publ) vs. peers: Other Current Liabilities Comparison

Loading

Aptahem AB (publ) Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Aptahem AB (publ) (APTA.ST) FAQ

Aptahem AB (publ)'s other current liabilities stands at $750K as of June 2026. That compares with $1.3M in the prior-year period — down 44.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Aptahem AB (publ) reported $750K in other current liabilities versus $1.3M a year earlier — a 44.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $1.3M in the prior-year period — down 44.2% year over year. Sustained growth in other current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Aptahem AB (publ)'s other current liabilities evolved across reporting periods, while the comparison chart places APTA.ST next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current liabilities is commonly used to spot outliers. Aptahem AB (publ)'s reading of $750K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.